LONGEVA.

Retatrutide dosing schedule

retatrutide dosage

> Updated:

Retatrutide (preset)

Calculate the Retatrutide dose

The calculator is already set up for Retatrutide — adjust the dose or diluent volume for your vial.

Open calculator

In short

Retatrutide is a triple GIP/GLP-1/glucagon agonist, given in studies as a once-weekly subcutaneous injection. The schedule on this page: start at 2.5 mg for 4 weeks, then increase every 4 weeks (5 → 10 mg), up to a maximum of 15 mg once weekly. The Phase 2 trial (Jastreboff and colleagues, NEJM, 2023) used different target doses – including 4, 8 and 12 mg – but the titration logic is the same.

Human dosing

Retatrutide dosing always runs through titration rather than a fixed target dose from week one, so the schedule below shows the escalation sequence, not a single number.

Period / conditionDoseEscalation
Start (weeks 1–4)2.5 mg once weekly subcutaneouslyStarting dose
Titration (every 4 weeks)5 → 10 mg once weeklyIncrease if needed
Upper bound of this schedule15 mg once weeklyMaximum in this schedule
Practical dosing and effect details

In the Phase 2 obesity trial (Jastreboff and colleagues, New England Journal of Medicine, 2023), retatrutide was given as a once-weekly subcutaneous injection, titrated every 4 weeks up to one of several target doses (including 4, 8, and 12 mg) rather than jumping straight to the maximum.

In that trial, higher maintenance doses produced greater average weight reduction at 24 and 48 weeks than lower ones, meaning the effect kept rising with dose across the studied range rather than plateauing right after the start.

The schedule on this page (2.5 mg start, titration to 5→10 mg, 15 mg maximum once weekly) is a commonly used practical version of the same approach: gradual dose escalation over several weeks rather than an immediate target dose. The exact doses tested in the Jastreboff trial itself (4, 8, and 12 mg) differ from this practical schedule, but the titration logic and the interval between increases are the same. A 4-week step between increases is typical for receptor agonists in this class (GIP/GLP-1/glucagon): the interval gives time to assess gastrointestinal tolerability before the next step, not just to reach a target blood concentration.

This is reference information drawn from a published trial and common usage practice, not a medical recommendation and not instructions for self-administration.

Frequently asked questions

What is the starting dose of retatrutide? 2.5 mg subcutaneously once weekly for the first 4 weeks. The dose is then increased every 4 weeks – 5, then 10 mg; the upper bound of the schedule on this page is 15 mg once weekly.

What doses were studied in Phase 2? Target doses included 4, 8 and 12 mg once weekly (Jastreboff and colleagues, NEJM, 2023). Higher maintenance doses produced greater average weight reduction at 24 and 48 weeks – the effect kept rising with dose across the studied range.

How many U-100 syringe units is a dose? It depends on the concentration of the reconstituted vial: units = dose (mg) divided by concentration (mg/mL) times 100. For example, at 10 mg/mL the 2.5 mg starting dose is 0.25 mL, i.e. 25 U-100 units.

Why is the dose increased only every 4 weeks? A 4-week step is typical for agonists of this class: the interval gives time to assess gastrointestinal tolerability before the next increase, not just to reach a target blood concentration.

How to reconstitute

An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.

  1. 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 5 mg vial.Retatrutide5 mg+ 2 mlDiluent
  2. 2Get the concentrationExample: 5 mg in 2 ml =Retatrutide2.5 mg/ml(2,500 mcg/ml)
  3. 3Work out the volume per doseFor example, for a 2 mg dose:2 mg = 0.8 ml= 80 u. (U-100)

This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →

Research protocols

Retatrutide: reference regimens

Retatrutide is a triple receptor agonist (GIP/GLP-1/glucagon) administered as a once-weekly subcutaneous injection in studies.

More scientific background in the Retatrutide monograph

Notes and safety

  • • Retatrutide is a research peptide. Human safety and efficacy data are limited.
  • • The regimens shown are based on publications and research protocols, not clinical recommendations.
  • • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
  • • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
  • • This information is for educational purposes and is not medical advice.
This is not medical advice — research information only.This material is not intended for diagnosis, treatment or prevention of disease.